000 | 01919 a2200529 4500 | ||
---|---|---|---|
005 | 20250515134718.0 | ||
264 | 0 | _c20090518 | |
008 | 200905s 0 0 eng d | ||
022 | _a1432-5233 | ||
024 | 7 |
_a10.1007/s00592-008-0055-6 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aChisalita, Simona I | |
245 | 0 | 0 |
_aDifferential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. _h[electronic resource] |
260 |
_bActa diabetologica _cMar 2009 |
||
300 |
_a35-42 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aApolipoproteins _xblood |
650 | 0 | 4 |
_aBlood Glucose _xdrug effects |
650 | 0 | 4 |
_aC-Peptide _xblood |
650 | 0 | 4 |
_aCarbamates _xtherapeutic use |
650 | 0 | 4 |
_aCholesterol _xblood |
650 | 0 | 4 | _aCross-Over Studies |
650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
650 | 0 | 4 | _aDrug Administration Schedule |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
650 | 0 | 4 |
_aInsulin _xanalogs & derivatives |
650 | 0 | 4 | _aInsulin Aspart |
650 | 0 | 4 |
_aInsulin-Like Growth Factor Binding Protein 1 _xblood |
650 | 0 | 4 |
_aInsulin-Like Growth Factor I _xmetabolism |
650 | 0 | 4 |
_aLipids _xblood |
650 | 0 | 4 |
_aLipoproteins _xblood |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aPiperidines _xtherapeutic use |
650 | 0 | 4 |
_aProinsulin _xblood |
700 | 1 | _aLindström, Torbjörn | |
700 | 1 | _aEson Jennersjö, Pär | |
700 | 1 | _aPaulsson, Johan F | |
700 | 1 | _aWestermark, Gunilla T | |
700 | 1 | _aOlsson, Anders G | |
700 | 1 | _aArnqvist, Hans J | |
773 | 0 |
_tActa diabetologica _gvol. 46 _gno. 1 _gp. 35-42 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00592-008-0055-6 _zAvailable from publisher's website |
999 |
_c18246578 _d18246578 |